<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03843398</url>
  </required_header>
  <id_info>
    <org_study_id>SINOCOLO2019C</org_study_id>
    <nct_id>NCT03843398</nct_id>
  </id_info>
  <brief_title>Survival Outcome After Minilaparotomy for the Treatment of Colorectal Cancer</brief_title>
  <acronym>SoMiniCRC</acronym>
  <official_title>Survival Outcome After Minilaparotomy for the Treatment of Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is

      - to determine the difference of survival outcome (3-year overall survival, 3y OS) between
      after minilaparotomy and after laparoscopy..

      Other aims include to determine the data below when minilaparotomy and laparoscopy are
      compared with each other.

        -  3-year disease free survival, 3y DFS

        -  5-year overall survival, 5y OS

        -  5-year disease free survival, 5y DFS

        -  Local recurrence rate, LRR

        -  Postoperative complications Incidence and mortality at 30 days
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year overall survival, 3y OS</measure>
    <time_frame>3 years after the follow up of the last patient enrolled.</time_frame>
    <description>3y OS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5-year overall survival, 5y OS</measure>
    <time_frame>5 years after the follow up of the last patient enrolled.</time_frame>
    <description>5y OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year disease free survival, 3y DFS</measure>
    <time_frame>3 years after the follow up of the last patient enrolled.</time_frame>
    <description>3y DFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year disease free survival, 3y DFS</measure>
    <time_frame>5 years after the follow up of the last patient enrolled.</time_frame>
    <description>5y DFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence rate, LRR</measure>
    <time_frame>3 years after the follow up of the last patient enrolled.</time_frame>
    <description>LRR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications Incidence at 30 days</measure>
    <time_frame>30 days after the operation of the last patient enrolled.</time_frame>
    <description>PCI30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative mortality at 30 days</measure>
    <time_frame>30 days after the operation of the last patient enrolled.</time_frame>
    <description>PM30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">992</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Minilaparotomy Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm undergo colorectal cancer resection via minilaparotomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopy Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this arm undergo laparoscopic colorectal cancer resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colorectal cancer resection via minilaparotomy</intervention_name>
    <description>According to the cancer location, a 7 cm incision is made in specific area of the patient's abdomen. The whole procedure of operation will be finished within this incision. If the incision must be lengthen due to the surgical demand, the failure of the minilaparotomy is determined.</description>
    <arm_group_label>Minilaparotomy Group</arm_group_label>
    <other_name>Minilaparotomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic colorectal cancer resection</intervention_name>
    <description>This is one of the routine procedures used for colorectal cancer resection.</description>
    <arm_group_label>Laparoscopy Group</arm_group_label>
    <other_name>Laparoscopy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Colorectal cancer with pathological results.

          -  Colorectal cancer preliminary diagnosed during colonoscopy.

          -  No confirmed metastasis.

          -  No comorbidity of other malignancy.

          -  The primary tumor is less than 10 cm.

          -  No organ dysfunction.

          -  The patient and his families totally agree with the whole investigative procedure, and
             sign the written informed consent form.

        Exclusion Criteria:

          -  Diagnosed with any other malignancy within 5 years.

          -  Comorbidity of emergent conditions like perforation.

          -  Former colorectal surgery history which may affects digestive tract reconstruction.

          -  Need combined organ resection.

          -  ASA grade IV or V.

          -  Pregnant or lactating Women.

          -  Severe mental diseases.

          -  Severe cardiopulmonary diseases which reduce operation tolerance.

          -  Systematic steroid therapy lasting for more than 1 month.

          -  Intolerant of laparoscopy.

          -  No written informed consent form signed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>En-Da YU, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zi-Ye ZHAO, MD</last_name>
    <phone>8618699629177</phone>
    <email>yemenzhao@126.com</email>
  </overall_contact>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23066325</url>
    <description>PubMed link</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/22026303</url>
    <description>PubMed link</description>
  </link>
  <reference>
    <citation>Wang XD, Huang MJ, Yang CH, Li K, Li L. Minilaparotomy to rectal cancer has higher overall survival rate and earlier short-term recovery. World J Gastroenterol. 2012 Oct 7;18(37):5289-94. doi: 10.3748/wjg.v18.i37.5289.</citation>
    <PMID>23066325</PMID>
  </reference>
  <reference>
    <citation>Ishida H, Ishiguro T, Ohsawa T, Okada N, Kumamoto K, Ishibashi K, Haga N, Yokoyama M, Nakada H, Gonda T. Oncologic outcome of stages II/III colon cancer treated via minilaparotomy. Int Surg. 2011 Apr-Jun;96(2):127-34.</citation>
    <PMID>22026303</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>En-Da Yu</investigator_full_name>
    <investigator_title>Director of Department of Colorectal Surgery and Vice Director of GI Endoscopy</investigator_title>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Minilaparotomy</keyword>
  <keyword>Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

